Industry
Biotechnology
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 11:42 am
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 10:33 am
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 10:33 am
Portfolio Pulse from Benzinga Newsdesk
May 21, 2024 | 11:59 am
Portfolio Pulse from Benzinga Newsdesk
May 20, 2024 | 5:46 am
Portfolio Pulse from Benzinga Newsdesk
May 16, 2024 | 5:01 pm
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 10:41 am
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 9:01 pm
Portfolio Pulse from Benzinga Newsdesk
May 06, 2024 | 3:08 pm
Portfolio Pulse from Benzinga Newsdesk
April 19, 2024 | 4:30 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.